Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection(QLG2174) in the Prevention of Post-operative Nausea and Vomiting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Wuhan, China
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged 18 to 70 years, with a body mass index (BMI) of 18-30 kg/m² and body weight≥45kg.
- laparoscopic gynecologic or abdominal surgery under general anesthesia (duration≥1 hour and postoperative hospitalization ≥24 hours), with anesthesia maintained using sevoflurane and remifentanil (propofol maintenance was prohibited);
- had≥2 risk factors of PONV; expected to use postoperative opioid within 24 hours after surgery;
- American Society of Anesthesiologists (ASA) physical status class I-III.
Exclusion Criteria:
- planned intrathoracic, transplant, or central nervous system surgeries;
- diagnostic-only procedures;
- use of local/regional anesthesia (e.g., neuraxial/nerve blocks);
- postoperative intensive care unit (ICU) transfer;
- preoperative nasogastric/orogastric tube placement (from screening through 24 hours postoperatively)
- nausea, vomiting, retching, or organic disease-related emesis (e.g., intestinal obstruction) within 24 hours preoperatively; history of malignancy, epilepsy, or vestibular dysfunction;
- hypersensitivity to aprepitant;
- recent use of aprepitant/NK1 antagonists (within 2 weeks prior to randomization), antiemetics (including 5-HT3 antagonists, corticosteroids; within 1 week), strong CYP3A4 inhibitors/substrates (within 1 week), CYP3A4 inducers (within 4 weeks), or warfarin (within 2 weeks);
- clinically significant laboratory abnormalities (ALT/AST ≥2×upper limit of normal [ULN], total bilirubin ≥1.5×ULN, creatinine ≥1.5×ULN, hemoglobin ≤90 g/L)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Aprepitant Injection
|
Before anesthesia induction, 4.4ml(32mg) was given by a single intravenous injection, which was completed within 30 seconds
|
|
Experimental: Aprepitant Injection Placebo
|
Before anesthesia induction, 4.4ml was given by a single intravenous injection, which was completed within 30 seconds
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete response (CR) rates over 24 hours after the end of surgery
Time Frame: 0-24 hours after the end of surgery
|
Complete response (defined as no emetic episodes and no use of rescue therapy
|
0-24 hours after the end of surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Postoperative Complications
- Pathologic Processes
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Postoperative Nausea and Vomiting
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antiemetics
- Autonomic Agents
- Peripheral Nervous System Agents
- Gastrointestinal Agents
- Neurotransmitter Agents
- Neurokinin-1 Receptor Antagonists
- Aprepitant
- Fosaprepitant
Other Study ID Numbers
Other Study ID Numbers
- QLG2174-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.